Novartis

Novartis UK is the British subsidiary of the Swiss multinational pharmaceutical company, developing innovative medicines in oncology, immunology, neuroscience, cardiovascular disease, and ophthalmology. Key products include Entresto (sacubitril/valsartan) for heart failure, Cosentyx (secukinumab) for psoriasis, Kesimpta (ofatumumab) for multiple sclerosis, and Kisqali (ribociclib) for breast cancer.